ORAMED PHARMACEUTICALS INC.
No enriched coverage for $ORMP in the last 7 days.
No SEC Form 4 filings for $ORMP in the last 30 days.
Oramed Pharmaceuticals Inc.'s Chief Scientific Officer, Miriam Kidron, reported a tax-related disposition of 435,084 common shares to cover tax withholding obligations from vested Restricted Stock Units. The shares were valued at $3.31 each. Following this transaction, Kidron directly holds 1,133,138 shares of Oramed common stock.
Oramed Pharmaceuticals Inc. announced that Scilex Holding Company has completed the repurchase of all remaining warrants previously held by Oramed to purchase shares of Scilex common stock, totaling $28.5 million for 6,500,000 shares. This transaction involved two tranches, with Scilex paying $14 million on December 30 for 3,370,000 warrants and an earlier $13 million on September 30 for 3,130,000 warrants, plus $1.5 million in option fees. These repurchases were part of an option agreement disclosed in July and follows other strategic adjustments for Oramed, including the termination of a joint venture and plans to independently advance its oral insulin program.
Oramed Pharmaceuticals finalized a warrant repurchase with Scilex totaling $28.5 million on December 30, 2025. This involved Scilex repurchasing 3,370,000 shares for $14 million and an initial tranche of 3,130,000 shares for $13 million, with each tranche including a $750,000 option fee. The details of this transaction were filed with the SEC.
